Santuza R. Teixeira

Belo Horizonte, MG, Brazil

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications

Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment.

Optimization and production of a GLP-grade recombinant Sm29 vaccine against schistosomiasis: From expression to preclinical assessment.

Journal: PLoS neglected tropical diseases
Published: April 19, 2026

Correction: RNA and protein immunization with Trypanosoma cruzi trans-sialidase containing SAPA repeats protects mice against infection and promotes a balanced inflammatory response.

Correction: RNA and protein immunization with Trypanosoma cruzi trans-sialidase containing SAPA repeats protects mice against infection and promotes a balanced inflammatory response.

Journal: Frontiers in cellular and infection microbiology
Published: October 20, 2025

RNA and protein immunization with Trypanosoma cruzi trans-sialidase containing SAPA repeats protects mice against infection and promotes a balanced inflammatory response.

RNA and protein immunization with Trypanosoma cruzi trans-sialidase containing SAPA repeats protects mice against infection and promotes a balanced inflammatory response.

Journal: Frontiers in cellular and infection microbiology
Published: August 07, 2025

The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine - preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice.

The LVD/NIAID/NIH MVA1974 clone as an Mpox vaccine - preclinical assessment upon in a model of lethal infection with Orthopoxvirus monkeypox in mice.

Journal: Vaccine
Published: July 07, 2025

Characterization of a novel Leishmania antigen containing a repetitive domain and its potential use as a prophylactic and therapeutic vaccine.

Characterization of a novel Leishmania antigen containing a repetitive domain and its potential use as a prophylactic and therapeutic vaccine.

Journal: mSphere
Published: April 22, 2025

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.

SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern.

Journal: Vaccine
Published: December 12, 2023

Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.

Evaluation of an RBD-nucleocapsid fusion protein as a booster candidate for COVID-19 vaccine.

Journal: iScience
Published: August 17, 2023

Disruption of the inositol phosphorylceramide synthase gene affects Trypanosoma cruzi differentiation and infection capacity.

Disruption of the inositol phosphorylceramide synthase gene affects Trypanosoma cruzi differentiation and infection capacity.

Journal: PLoS neglected tropical diseases
Published: September 30, 2022

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.

Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern.

Journal: NPJ vaccines
Published: August 26, 2022

ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.

ASP-2/Trans-sialidase chimeric protein induces robust protective immunity in experimental models of Chagas' disease.

Journal: NPJ vaccines
Published: June 07, 2022

Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19.

Development and validation of an enzyme-linked immunoassay kit for diagnosis and surveillance of COVID-19.

Journal: Journal of clinical virology plus
Published: May 30, 2022

Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.

Promotion of neutralizing antibody-independent immunity to wild-type and SARS-CoV-2 variants of concern using an RBD-Nucleocapsid fusion protein.

Journal: Nature communications
Published: April 15, 2022
Showing 1-12 of 37

Last Updated: 09/26/2026